Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF – Get Free Report) was up 119.8% during mid-day trading on Tuesday . The stock traded as high as $20.00 and last traded at $20.00. Approximately 101 shares were traded during trading, a decline of 83% from the average daily volume of 600 shares. The stock had previously closed at $9.10.
Newron Pharmaceuticals Price Performance
The business’s 50-day moving average price is $9.57 and its 200 day moving average price is $9.43.
Newron Pharmaceuticals Company Profile
Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.
Newron’s lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson’s disease.
Read More
Receive News & Ratings for Newron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Newron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
